Opakalim

Opakalim
Clinical data
Other names	BHV-7000; BHV7000; BPN-25203; BPN25203; KB-3061; KB3061
Routes of; administration	Oral
Drug class	Kv7.2 and Kv7.3 potassium channel opener
Identifiers
	IUPAC name N-(1-tert-butyl-6-cyano-4,7-difluorobenzimidazol-2-yl)-3,3-dimethylbutanamide;
CAS Number	2376397-93-0;
PubChem CID	139487180;
DrugBank	DB22041;
ChemSpider	129910012;
UNII	73H9J7RBA2;
KEGG	D13061;
Chemical and physical data
Formula	C18H22F2N4O
Molar mass	348.398 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)CC(=O)NC1=NC2=C(C=C(C(=C2N1C(C)(C)C)F)C#N)F;
	InChI InChI=1S/C18H22F2N4O/c1-17(2,3)8-12(25)22-16-23-14-11(19)7-10(9-21)13(20)15(14)24(16)18(4,5)6/h7H,8H2,1-6H3,(H,22,23,25); Key:VOPRSHDHZUHPBT-UHFFFAOYSA-N;

Opakalim (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names BHV-7000, BPN-25203, and KB-3061) is a highly selective K_v7.2 and K_v7.3 potassium channel opener which is under development for the treatment of bipolar disorders, epilepsy, partial epilepsies, major depressive disorder, erythromelalgia, pain, infantile spasms, and mood disorders.^[1]^[2]^[3]^[4] It is taken orally.^[1] The drug was originated by Channel Biosciences and was under development by Biohaven Pharmaceuticals or Biohaven Therapeutics.^[1]^[2] As of April 2026, it is in phase 2/3 clinical trials for bipolar disorders, epilepsy, and partial epilepsies, phase 2 trials for major depressive disorder, and phase 1 trials for erythromelalgia and pain, whereas no recent development has been reported for infantile spasms and mood disorders.^[1]^[2] A phase 2 trial for major depressive disorder failed to meet its primary efficacy endpoint, resulting in focus more on epilepsy instead.^[3]

References

1 2 3 4 5 "Biohaven Pharmaceuticals". AdisInsight. 15 April 2026. Retrieved 31 May 2026.
1 2 3 "Delving into the Latest Updates on Opakalim with Synapse". Synapse. 2 April 2026. Retrieved 31 May 2026.
1 2 Pelorosso C, Balestrini S, Guerrini R (May 2026). "Potassium channel agonists emerging as treatment options for focal epilepsy: are we breaking new ground?". Expert Opinion on Emerging Drugs: 1–8. doi:10.1080/14728214.2026.2675274. PMID 42153277.
↑ Pong AW (December 2025). "Expanding the toolkit: An update on the evolution of new therapies for Lennox-Gastaut Syndrome". Seminars in Pediatric Neurology. 56 101242. doi:10.1016/j.spen.2025.101242. PMID 41371876.

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

[AdisInsight-1] 1 2 3 4 5 "Biohaven Pharmaceuticals". AdisInsight. 15 April 2026. Retrieved 31 May 2026.

[Synapse-2] 1 2 3 "Delving into the Latest Updates on Opakalim with Synapse". Synapse. 2 April 2026. Retrieved 31 May 2026.

[PelorossoBalestriniGuerrini2026-3] 1 2 Pelorosso C, Balestrini S, Guerrini R (May 2026). "Potassium channel agonists emerging as treatment options for focal epilepsy: are we breaking new ground?". Expert Opinion on Emerging Drugs: 1–8. doi:10.1080/14728214.2026.2675274. PMID 42153277.

[Pong2025-4] Pong AW (December 2025). "Expanding the toolkit: An update on the evolution of new therapies for Lennox-Gastaut Syndrome". Seminars in Pediatric Neurology. 56 101242. doi:10.1016/j.spen.2025.101242. PMID 41371876.

[1]

[2]

[3]

[4]

See also

References